☰

arjun muralidharan, B.Pharm (Hons.)

Affiliations: 
Pharmacology University of Queensland, Saint Lucia, Queensland, Australia 
Area:
Neuropathic pain
Google:
"arjun muralidharan"
Mean distance: 106866 (cluster 37)
 		SNBCP
Tree Publications Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

Parents

Sign in to add mentor
Vaigunda Ragavendran Jegadeesan research assistant 2006-2008

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Khan N, Muralidharan A, Smith MT. (2017) Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia - A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. Frontiers in Molecular Neuroscience. 10: 389
Muralidharan A, Park TSW, Mackie JT, et al. (2017) Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. Frontiers in Pharmacology. 8: 493
Muralidharan A, Kuo A, Jacob M, et al. (2016) Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience. 10: 88
Smith MT, Muralidharan A. (2015) Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion On Therapeutic Targets. 19: 25-35
Muralidharan A, Wyse BD, Smith MT. (2014) Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain. Pain Medicine (Malden, Mass.). 15: 93-110
Muralidharan A, Smith MT. (2013) Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology. 21: 339-63
Smith MT, Woodruff TM, Wyse BD, et al. (2013) A small molecule angiotensin II type 2 receptor (ATâ‚‚R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Medicine (Malden, Mass.). 14: 1557-68
Muralidharan A, Wyse BD, Smith MT. (2013) Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology, Biochemistry, and Behavior. 106: 33-46
Smith MT, Muralidharan A. (2012) Pharmacogenetics of pain and analgesia. Clinical Genetics. 82: 321-30
Muralidharan A, Smith MT. (2011) Pain, analgesia and genetics. The Journal of Pharmacy and Pharmacology. 63: 1387-400
See more...